SRSF1 Regulates the Alternative Splicing of Caspase 9 Via A Novel Intronic Splicing Enhancer Affecting the Chemotherapeutic Sensitivity of Non–Small Cell Lung Cancer Cells
- 1 July 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 9 (7) , 889-900
Abstract
Increasing evidence points to the functional importance of alternative splice variations in cancer pathophysiology with the alternative pre-mRNA processing of caspase 9 as one example. In this study, we delve into the underlying molecular mechanisms that regulate the alternative splicing of caspase 9. Specifically, the pre-mRNA sequence of caspase 9 was analyzed for RNA cis-elements known to interact with SRSF1, a required enhancer for caspase 9 RNA splicing. This analysis revealed 13 possible RNA cis-elements for interaction with SRSF1 with mutagenesis of these RNA cis-elements identifying a strong intronic splicing enhancer located in intron 6 (C9-I6/ISE). SRSF1 specifically interacted with this sequence, which was required for SRSF1 to act as a splicing enhancer of the inclusion of the 4 exon cassette. To further determine the biological importance of this mechanism, we employed RNA oligonucleotides to redirect caspase 9 pre-mRNA splicing in favor of caspase 9b expression, which resulted in an increase in the IC50 of non–small cell lung cancer (NSCLC) cells to daunorubicin, cisplatinum, and paclitaxel. In contrast, downregulation of caspase 9b induced a decrease in the IC50 of these chemotherapeutic drugs. Finally, these studies showed that caspase 9 RNA splicing was a major mechanism for the synergistic effects of combination therapy with daunorubicin and erlotinib. Overall, we have identified a novel intronic splicing enhancer that regulates caspase 9 RNA splicing and specifically interacts with SRSF1. Furthermore, we showed that the alternative splicing of caspase 9 is an important molecular mechanism with therapeutic relevance to NSCLCs. Mol Cancer Res; 9(7); 889–900. ©2011 AACR.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Alternative Splicing of Caspase 9 Is Modulated by the Phosphoinositide 3-Kinase/Akt Pathway via Phosphorylation of SRp30aCancer Research, 2010
- hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processingJournal of Clinical Investigation, 2010
- An Alternative Splicing Network Links Cell-Cycle Control to ApoptosisCell, 2010
- ASTD: The Alternative Splicing and Transcript Diversity databaseGenomics, 2009
- The gene encoding the splicing factor SF2/ASF is a proto-oncogeneNature Structural & Molecular Biology, 2007
- De Novo Ceramide Regulates the Alternative Splicing of Caspase 9 and Bcl-x in A549 Lung Adenocarcinoma CellsJournal of Biological Chemistry, 2002
- FAS Activation Induces Dephosphorylation of SR ProteinsJournal of Biological Chemistry, 2001
- Defective caspase-3 relocalization in non-small cell lung carcinomaOncogene, 2001
- Ceramide Mediates the Apoptotic Response of WEHI 231 Cells to Anti-immunoglobulin, Corticosteroids and IrradiationBiochemical and Biophysical Research Communications, 1994
- Competitive PCRNature, 1992